TXNIP and type 2 diabetes mellitus: Overall, the present study evidently showed that quinazoline nitrogen-containing heterocyclic derivatives to inhibit TXNIP would be potent pancreatic β cell protective agents and compounds D-2 and C-1, especially the compound D-2, might serve as promising lead candidates for the treatment of T2DM.